Subtype
Malignant Urinary Tract Neoplasm
CI-CAN-00003252Explore in graph →
507 active trials14 approved drugs29 evidence items
- NCIt
- C192668
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003252Explore in graph →
Clinical trials
1,955 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (246)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05621837 | Quantifying Systemic Immunosuppression to Personalize Cancer Therapy(Serpentine) | recruiting | — | 1,000 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT06926374 | Prospective Evaluation of Cornerstone Robotics Sentire Surgical System in Major Gastrointestinal and Urologic Surgery | recruiting | N/A | 90 | Chinese University of Hong KongOTHER | 1 |
| Apr 16, 2025 |
| clinicaltrials |
| NCT06196736 | A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer | recruiting | Phase 3 | 432 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Apr 13, 2025 | clinicaltrials |
| NCT00938145 | 3 Tesla MRI in Patients With Bladder Cancer | active not recruiting | N/A | 98 | University of CincinnatiOTHER | 1 | Apr 11, 2025 | clinicaltrials |
| NCT06912672 | Performance Evaluation of a Urine-based Methylation Assay for Urothelial Carcinoma(UMT-UC) | not yet recruiting | — | 1,500 | Shanghai Epiprobe Biotechnology Co., Ltd.INDUSTRY | 0 | Apr 8, 2025 | clinicaltrials |
| NCT06257017 | Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma | recruiting | Phase 2 | 20 | Yung NAOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06493552 | Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors | recruiting | Phase 2 / Phase 3 | 700 | Vasgene Therapeutics, IncINDUSTRY | 1 | Apr 3, 2025 | clinicaltrials |
| NCT05290038 | ARON-2 Study-Multicentric International Retrospective Study | recruiting | — | 367 | Matteo SantoniOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT06904573 | Probiotics in Advanced Urothelial Carcinoma(IMPROVE) | recruiting | Phase 2 | 222 | Sun Yat-sen UniversityOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT06766266 | Irinotecan Liposomes Combined with Epirubicin in Recurrent Non-muscle Invasive Bladder Urothelium Carcinoma After Anthracyclines Treatment | recruiting | Phase 1 | 18 | First Affiliated Hospital of Chongqing Medical UniversityOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT04046094 | Intravenous (IV) Vitamin C With Chemotherapy for Cisplatin Ineligible Bladder Cancer Patients | active not recruiting | Phase 1 / Phase 2 | 12 | University of Kansas Medical CenterOTHER | 1 | Mar 25, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06823427 | 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma | recruiting | Phase 2 | 60 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06889623 | Immediate Chemotherapy Following Resection for High-Risk Non-Muscle-Invasive Bladder Cancer(HIGCrecur) | recruiting | N/A | 72 | Changhai HospitalOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06735287 | A Bladder-Sparing Treatment Strategies of Large-Volume Non-Muscle-Invasive Bladder Cancer | recruiting | N/A | 60 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 18, 2025 | clinicaltrials |
| NCT06763354 | The Efficacy of Gallium[68Ga]NOTA-DNA Multivalent SGC8 Injection for Bladder Tumour Imaging | recruiting | N/A | 20 | RenJi HospitalOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT06878027 | Analysis of Urinary Methylation Patterns Via Liquid Biopsy as an Early Diagnosis Tool | recruiting | — | 100 | Regina Elena Cancer InstituteOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT04510129 | A Multicenter Cancer Biospecimen Collection Study | recruiting | — | 1,650 | Cofactor Genomics, Inc.INDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT02202772 | Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder(CGC) | active not recruiting | Phase 1 / Phase 2 | 51 | Guarionex J. DecastroOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT05231655 | Ex VIvo DEtermiNed Cancer Therapy(EVIDENT) | recruiting | — | 600 | Sheffield Teaching Hospitals NHS Foundation TrustOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT06364904 | A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma. | not yet recruiting | Phase 3 | 210 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT06493370 | Intravenous Ascorbate Plus Gemcitabine/Carboplatin: A Novel and Cost-Effective Alternative With Evident Efficacy in Patients With Muscle Invasive Bladder Cancer | recruiting | Phase 2 | 48 | University of Kansas Medical CenterOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT06696794 | Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients | recruiting | Phase 3 | 180 | Shaogang WangOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT02951325 | Bladder Cancer Adjuvant Radiotherapy Trial(BART) | active not recruiting | Phase 3 | 153 | Tata Memorial CentreOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT06337942 | Deceased Donor Bladder or Combined Kidney-bladder Transplantation: a Phase 0 First-in-human Study | recruiting | N/A | 5 | University of California, Los AngelesOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT06820502 | OUTCOMES of SIMULTANEOUS TRANSURETHRAL PROSTATE and BLADDER TUMOR RESECTION VERSUS TRANSURETHRAL BLADDER TUMOR RESECTION in BLADDER TUMOR with BLADDER PROSTATE HYPERPLASIA | active not recruiting | N/A | 60 | Allama Iqbal Medical CollegeOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT06281080 | First-in-Human Trial of a Novel Endoluminal Robotic System for En-Bloc Resection of Bladder Tumours | recruiting | N/A | 10 | Chinese University of Hong KongOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT03212404 | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | active not recruiting | Phase 1 | 272 | Checkpoint Therapeutics, Inc.INDUSTRY | 9 | Feb 3, 2025 | clinicaltrials |
| NCT06798246 | HEFTME System for Adjuvant Therapeutic Selection of Locally Advanced UTUC Postoperatively：A Perspective Cohort Study | not yet recruiting | — | 200 | Peking University First HospitalOTHER | 0 | Jan 29, 2025 | clinicaltrials |
| NCT06775977 | Ultrasound Contrast-Enhanced Accurate Diagnosis of Preoperative Staging of Bladder Cancer(UCEADP-BCS) | recruiting | — | 480 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT05917158 | A Study of RC48-ADC Combined with JS001 for Postoperative Adjuvant Treatment of Upper Tract Urothelial Carcinoma(1) | recruiting | Phase 2 | 30 | Jinling Hospital, ChinaOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06780358 | Study of bladdeR Cancer Detection in Standard White Light Versus AI-Supported Endoscopy-02(RAISE02) | enrolling by invitation | N/A | 64 | CystotechINDUSTRY | 1 | Jan 17, 2025 | clinicaltrials |
| NCT04724928 | Evaluating the Impact of 18F-FDG-PET-CT on Risk Stratification and Treatment Adaptation for Patients with Muscle Invasive Bladder Cancer(EFFORT-MIBC) | recruiting | Phase 2 | 156 | University Hospital, GhentOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06186414 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC | recruiting | Phase 1 | 152 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 15, 2025 | clinicaltrials |
| NCT05204108 | Preoperative Detection of Muscle Invasion in Bladder Cancer with Contrast-enhanced Ultrasonography | recruiting | — | 1,000 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT06732531 | Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer | recruiting | Phase 1 / Phase 2 | 48 | Zhuhai Beihai Biotech Co., LtdINDUSTRY | 1 | Jan 9, 2025 | clinicaltrials |
| NCT06762925 | Study on the Efficacy and Mechanism of METTL3 Peptide Inhibitors in Enhancing Anti-tumor Immune Response by Reshaping the Tumor Microenvironment | not yet recruiting | — | 450 | Xijing HospitalOTHER | 0 | Jan 8, 2025 | clinicaltrials |
| NCT06751667 | Xpert Bladder Monitor: a Non-Invasive Follow-Up Tool for Detecting Relapse in High Grade or High Risk Bladder Cancer(LIBERO) | not yet recruiting | N/A | 50 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 0 | Dec 30, 2024 | clinicaltrials |
| NCT05790850 | Pre-Habilitation with Mindfulness and Exercise for Patients Undergoing Radical Cystectomy (PRIMER Trial)(PRIMER) | recruiting | N/A | 30 | University of VirginiaOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06719232 | Evaluating the Efficacy and Patient Experience of Catheter-Free Intravesical Instillation(NOCATIN) | recruiting | — | 300 | Jahn Ferenc South Pest Teaching HospitalOTHER_GOV | 1 | Dec 12, 2024 | clinicaltrials |
| NCT03799835 | Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients(ALBAN) | active not recruiting | Phase 3 | 517 | UNICANCEROTHER | 3 | Dec 11, 2024 | clinicaltrials |
| NCT06679920 | Study With a Newly Optical Coherence Tomography Probe for Optimizing Bladder Cancer Diagnosis and Treatment(BLOCT) | recruiting | N/A | 15 | Amsterdam UMCOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT04289779 | Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer(ABATE) | active not recruiting | Phase 2 | 46 | Deepak KilariOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT04562311 | Chidamide With Immunotherapy for Patients With Locally Advanced or Metastatic Urothelial Carcinoma | active not recruiting | Phase 2 | 45 | Sun Yat-sen UniversityOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT04861584 | Neoadjuvant Toripalimab in Combination with Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects | recruiting | Phase 2 | 41 | Zhujiang HospitalOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT05067101 | Comparison Capsule Sparing Cystectomy and Radical Cystoprostatectomy in Men with Bladder Cancer | recruiting | N/A | 126 | Zhujiang HospitalOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT06341400 | RC48 Combined with Toripalimab As Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients | recruiting | Phase 1 / Phase 2 | 55 | Zhujiang HospitalOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT05453682 | Hypofractionated IMRT With Concurrent Chemotherapy in Muscle-invasive Bladder Cancer (HIRACUM)(HIRACOM) | recruiting | N/A | 53 | Samsung Medical CenterOTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT06119724 | Bipolar Enbloc Versus Thulium-Yag Enbloc Resection of Bladder Tumors(TURBT-Enbloc) | active not recruiting | N/A | 50 | Menoufia UniversityOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT06632262 | A Phase 2 Clinical Study of ABSK061 and ABSK043 | recruiting | Phase 2 | 202 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
Data updated 23 days agoSource updated May 2, 2025source: clinicaltrials